Sinopharm ZHIJUN(Shenzhen)PHARMACEUTICAL Co., Ltd.

It has a wide range of antibacterial spectrum against Gram-positive and Gram-negative bacteria, especially against Staphylococcus and Streptococcus among Gram-positive bacteria. It has stronger antibacterial activity than previous oral cephalosporins, and its mode of action is bactericidal. It is stable against beta-lactamase produced by various bacteria, and also has excellent antibacterial activity against beta-lactamase producing bacteria. The mechanism of action is to prevent the synthesis of bacterial cell walls, and it has a strong affinity for penicillin binding proteins (PBP) 1 (1a.lbs), 2, and 3, but the active sites for different bacteria are different.

Not yet clear

The third generation of oral cephalosporins kill bacteria by inhibiting bacterial cell wall synthesis. They are stable to most β-lactamases and have good antibacterial effects on Gram-positive cocci such as pneumococci and Streptococcus pyogenes, and Gram-negative bacilli such as Haemophilus influenzae (including enzyme-producing strains), Moraxella catarrhalis (including enzyme-producing strains), Escherichia coli, Proteus mirabilis, and Neisseria gonorrhoeae (including enzyme-producing strains). In vitro, they also have antibacterial activity against Streptococcus pneumoniae, Parainfluenzae, Proteus vulgaris, Klebsiella pneumoniae, Pasteurella multocida, Providencia, Salmonella, Shigella, Serratia marcescens, Citrobacter heteromorphis, and Citrobacter malonate, but their clinical effectiveness has not yet been established. They have poor antibacterial effects on Staphylococcus, and have no antibacterial effects on Pseudomonas aeruginosa, Enterobacter, Bacteroides fragilis, and Clostridium.

The third generation of oral cephalosporins kills bacteria by inhibiting bacterial cell wall synthesis. They are stable to most beta-lactamases, and many strains producing penicillinase and cephalosporinase are still sensitive to them. They have good antibacterial effects on Gram-positive cocci such as pneumococci and Streptococcus pyogenes, and Gram-negative bacilli such as Haemophilus influenzae (including enzyme-producing strains), Moraxella catarrhalis (including enzyme-producing strains), Escherichia coli, Proteus mirabilis, and Neisseria gonorrhoeae (including enzyme-producing strains). In vitro, they also have antibacterial activity against Streptococcus pneumoniae, Parainfluenzae, Proteus vulgaris, Klebsiella pneumoniae, Pasteurella multocida, Providencia, Salmonella, Shigella, Serratia marcescens, Citrobacter heteromorphis, and Citrobacter malonate, but their clinical effectiveness has not yet been established. They have poor antibacterial effects on Staphylococcus, and have no antibacterial effects on Pseudomonas aeruginosa, Enterobacter, Bacteroides fragilis, Clostridium, etc.

Cefuroxime axetil is a prodrug of cefuroxime. The mechanism of action of cefuroxime is to inhibit the synthesis of bacterial cell walls, so that bacteria cannot grow and reproduce. Cefuroxime has a broad-spectrum antibacterial effect, and has a strong antibacterial effect on Streptococcus pyogenes, Pneumococcus, Staphylococcus aureus methicillin-sensitive bacteria, Moraxella catarrhalis, Neisseria gonorrhoeae, and Haemophilus influenzae. It has a good effect on Enterobacteriaceae such as Escherichia coli, Klebsiella pneumoniae, and Proteus, but Pseudomonas aeruginosa and other Pseudomonas, Acinetobacter, and Enterococci are resistant.